Xenopatients 2.0 reprogrammingthe epigenetic landscapes of patient-derived cancer genomes

Cell Cycle

Volumn 13, Issue 3, 2014, Pages 358-370

  Menendez, Javier A ^a,b   Alarcón, Tomás ^c   Corominas Faja, Bruna ^a,b   Cuyàs, Elisabet ^a,b   López Bonet, Eugeni ^d   Martin, Ángel G ^e   Vellon, Luciano ^f  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c CENTRE DE RECERCA MATEMÀTICA   (Spain)

^d HOSPITAL JOSEP TRUETA   (Spain)

^e StemTek Therapeutics   (Spain)

^f INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

Cancer stem cells; Differentiation; Epigenetic landscape; iPS cells; Mouse avatars; Reprogramming; Stem cells; Xenografts; Yamanaka

Indexed keywords

ADULT STEM CELL; APOPTOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL RENEWAL; CELL SURVIVAL; CHROMOSOME ABERRATION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; NONHUMAN; NUCLEAR REPROGRAMMING; PLASTICITY; REVIEW; RNA INTERFERENCE; TUMOR GENE; TUMOR GROWTH; ANIMAL; GENETIC EPIGENESIS; GENETICS; GENOME; HUMAN GENOME; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; TRANSLATIONAL RESEARCH; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; EPIGENESIS, GENETIC; GENOME; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; MICE; NEOPLASMS; NEOPLASTIC STEM CELLS; PLURIPOTENT STEM CELLS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84896838573     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.27770     Document Type: Review

References (92)

1. Bond JA, Oddweig Ness G, Rowson J, Ivan M, White D, Wynford-Thomas D. Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression? Int J Cancer 1996; 67:563-72; PMID:8759617; http://dx.doi.org/10.1002/(SICI) 1097-0215(19960807)67:4〈563: :AID-IJC16〉3.0.CO;2-8
2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-76; PMID:16904174; http://dx.doi.org/10.1016/j.cell.2006.07.024
3. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007; 2:3081-9; PMID:18079707; http://dx.doi.org/10.1038/nprot.2007.418
4. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17:313-9; PMID:21386835; http://dx.doi.org/10.1038/nm.2304
5. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467-72; PMID:21430775; http://dx.doi.org/10.1038/nature09837
6. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470:214-20; PMID:21307934; http://dx.doi.org/10.1038/nature09744
7. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472:90-4; PMID:21399628; http://dx.doi.org/10.1038/ nature09807
8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; PMID:9212098; http://dx.doi.org/10.1038/nm0797-730
9. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11; PMID:11689955; http://dx.doi.org/10. 1038/35102167
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-8; PMID:12629218; http://dx.doi.org/10.1073/pnas. 0530291100
11. Pierce GB, Speers WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988; 48:1996-2004; PMID:2450643
12. Kleinsmith LJ, Pierce GB Jr. Multipotentiality of single embryonal carcinoma cells. Cancer Res 1964; 24:1544-51; PMID:14234000
13. Passegué E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA 2003; 100(Suppl 1):11842-9; PMID:14504387; http://dx.doi.org/10.1073/pnas.2034201100
14. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03.027
15. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009; 139:693-706; PMID:19878981; http://dx.doi.org/10. 1016/j.cell.2009.10.014
16. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 2011; 146:633-44; PMID:21854987; http://dx.doi.org/10.1016/j.cell.2011.07.026
17. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 2011; 108:7950-5; PMID:21498687; http://dx.doi.org/10.1073/pnas.1102454108
18. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 2011; 108:1397-402; PMID:21220315; http://dx.doi.org/10.1073/pnas.1018898108
19. Polytarchou C, Iliopoulos D, Struhl K. An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci USA 2012; 109:14470-5; PMID:22908280; http://dx.doi.org/10.1073/pnas. 1212811109
20. Spike BT, Wahl GM. p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer 2011; 2:404-19; PMID:21779509; http://dx.doi.org/10.1177/1947601911410224
21. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009; 138:822-9; PMID:19737509; http://dx.doi.org/10.1016/j.cell.2009.08.017
22. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21:283-96; PMID:22439924; http://dx.doi.org/10.1016/j.ccr.2012.03.003
23. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501:328-37; PMID:24048065; http://dx.doi.org/10.1038/nature12624
24. Abollo-Jiménez F, Jiménez R, Cobaleda C. Physiological cellular reprogramming and cancer. Semin Cancer Biol 2010; 20:98-106; PMID:20188173; http://dx.doi.org/10.1016/j.semcancer.2010.02.002
25. Castellanos A, Vicente-Dueñas C, Campos-Sánchez E, Cruz JJ, García-Criado FJ, García-Cenador MB, Lazo PA, Pérez-Losada J, Sánchez-García I. Cancer as a reprogramming-like disease: implications in tumor development and treatment. Semin Cancer Biol 2010; 20:93-7; PMID:20188174; http://dx.doi.org/10.1016/j.semcancer.2010.02.001
26. Ohm JE, Mali P, Van Neste L, Berman DM, Liang L, Pandiyan K, Briggs KJ, Zhang W, Argani P, Simons B, et al. Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. Cancer Res 2010; 70:7662-73; PMID:20841480; http://dx.doi.org/10.1158/0008-5472.CAN-10-1361
27. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R, Martin AG. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2012; 31:1354-65; PMID:21822303; http://dx.doi.org/10.1038/onc.2011.338
28. Corominas-Faja B, Cufí S, Oliveras-Ferraros C, Cuyàs E, López-Bonet E, Lupu R, Alarcón T, Vellon L, Iglesias JM, Leis O, et al. Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle 2013; 12:3109-24; PMID:23974095; http://dx.doi.org/10.4161/cc.26173
29. Vazquez-Martin A, Cufí S, López-Bonet E, Corominas-Faja B, Cuyàs E, Vellon L, Iglesias JM, Leis O, Martín AG, Menendez JA. Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells. Cell Cycle 2013; 12:3471-7; PMID:24107627; http://dx.doi.org/10.4161/cc.26692
30. Suvà ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science 2013; 339:1567-70; PMID:23539597; http://dx.doi.org/10.1126/ science.1230184
31. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993; 74:813-22; PMID:8374952; http://dx.doi.org/10.1016/0092-8674(93)90461-X
32. Tapia N, Schöler HR. p53 connects tumorigenesis and reprogramming to pluripotency. J Exp Med 2010; 207:2045-8; PMID:20876313; http://dx.doi.org/10. 1084/jem.20101866
33. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008; 455:1129-33; PMID:18948956; http://dx.doi.org/10.1038/nature07443
34. Zhao T, Xu Y. p53 and stem cells: new developments and new concerns. Trends Cell Biol 2010; 20:170-5; PMID:20061153; http://dx.doi.org/10.1016/j.tcb. 2009.12.004
35. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140:62-73; PMID:20074520; http://dx.doi.org/10.1016/j.cell.2009.12. 007
36. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010; 18:510-23; PMID:21075313; http://dx.doi.org/10.1016/j.ccr.2010.10.012
37. Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E, Vonderhaar BK. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res 2010; 70:4624-33; PMID:20484027; http://dx.doi.org/10.1158/0008-5472.CAN-09-3619
38. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008; 134:62-73; PMID:18614011; http://dx.doi.org/10.1016/j.cell.2008.06.006
39. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17:211-5; PMID:21240262; http://dx.doi.org/10.1038/nm.2284
40. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 2011; 108:4274-80; PMID:21262804; http://dx.doi.org/10.1073/pnas.1016030108
41. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141:69-80; PMID:20371346; http://dx.doi.org/10.1016/j.cell.2010.02.027
42. Hough SR, Laslett AL, Grimmond SB, Kolle G, Pera MF. A continuum of cell states spans pluripotency and lineage commitment in human embryonic stem cells. PLoS One 2009; 4:e7708; PMID:19890402; http://dx.doi.org/10.1371/journal.pone. 0007708
43. Shu J, Wu C, Wu Y, Li Z, Shao S, Zhao W, Tang X, Yang H, Shen L, Zuo X, et al. Induction of pluripotency in mouse somatic cells with lineage specifiers. Cell 2013; 153:963-75; PMID:23706735; http://dx.doi.org/10.1016/j.cell.2013.05. 001
44. Montserrat N, Nivet E, Sancho-Martinez I, Hishida T, Kumar S, Miquel L, Cortina C, Hishida Y, Xia Y, Esteban CR, et al. Reprogramming of human fibroblasts to pluripotency with lineage specifiers. Cell Stem Cell 2013; 13:341-50; PMID:23871606; http://dx.doi.org/10.1016/j.stem.2013.06.019
45. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisúa Belmonte JC. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460:1140-4; PMID:19668186; http://dx.doi.org/10.1038/nature08311
46. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009; 460:1132-5; PMID:19668191; http://dx.doi.org/10. 1038/nature08235
47. Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, Blasco MA, Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009; 460:1136-9; PMID:19668188; http://dx.doi.org/10. 1038/nature08290
48. Marión RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009; 460:1149-53; PMID:19668189; http://dx.doi.org/10.1038/nature08287
49. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009; 460:1145-8; PMID:19668190; http://dx.doi.org/10.1038/nature08285
50. Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O, Rotter V. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med 2010; 207:2127-40; PMID:20696700; http://dx.doi.org/10.1084/jem.20100797
51. Assou S, Le Carrour T, Tondeur S, Ström S, Gabelle A, Marty S, Nadal L, Pantesco V, Réme T, Hugnot JP, et al. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells 2007; 25:961-73; PMID:17204602; http://dx.doi.org/10.1634/stemcells. 2006-0352
52. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40:499-507; PMID:18443585; http://dx.doi.org/10.1038/ng.127
53. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, Cantor AB, Orkin SH. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010; 143:313-24; PMID:20946988; http://dx.doi.org/10.1016/j.cell.2010.09.010
54. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008; 2:333-44; PMID:18397753; http://dx.doi.org/10.1016/j.stem.2008.02.009
55. Mizuno H, Spike BT, Wahl GM, Levine AJ. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci USA 2010; 107:22745-50; PMID:21149740; http://dx.doi.org/10.1073/pnas. 1017001108
56. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12:4652-61; PMID:16899615; http://dx.doi.org/10.1158/1078-0432.CCR-06- 0113
57. Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 2008; 68:2841-9; PMID:18413752; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-5200
58. Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García E, López-Ríos F, Matsui W, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009; 8:310-4; PMID:19174553; http://dx.doi.org/10.1158/1535-7163.MCT-08-0924
59. Calles A, Rubio-Viqueira B, Hidalgo M. Primary human non-small cell lung and pancreatic tumorgraft models-utility and applications in drug discovery and tumor biology. Curr Protoc Pharmacol 2013;Chapter 14:Unit 14.26.
60. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1:508-23; PMID:22586653; http://dx.doi.org/10.1158/2159-8290.CD-11-0109
61. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models. [Epub ahead of print]. Oncogene 2013; •••: http://dx.doi.org/10.1038/ onc.2013.321; PMID:23934194
62. Reyes G, Villanueva A, García C, Sancho FJ, Piulats J, Lluís F, Capellá G. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res 1996; 56:5713-9; PMID:8971180
63. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, et al. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin Cancer Res 2009; 15:3384-95; PMID:19417025; http://dx.doi.org/10. 1158/1078-0432.CCR-08-2170
64. Vidal A, Muñoz C, Guillén MJ, Moretó J, Puertas S, Martínez-Iniesta M, Figueras A, Padullés L, García- Rodriguez FJ, Berdiel-Acer M, et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res 2012; 18:5399-411; PMID:22896654; http://dx.doi.org/10.1158/1078-0432.CCR-12-1513
65. Yaffe MB. The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment. Sci Signal 2013; 6:pe13; PMID:23550209; http://dx.doi.org/10.1126/scisignal.2003684
66. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009; 27:1050-6; PMID:19415771; http://dx.doi.org/10.1002/stem.37
67. Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, Kuperwasser N, Motola DL, Meissner TB, Hendriks WT, et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013; 12:238-51; PMID:23246482; http://dx.doi.org/10.1016/j.stem.2012.11.011
68. Musunuru K. Genome editing of human pluripotent stem cells to generate human cellular disease models. Dis Model Mech 2013; 6:896-904; PMID:23751357; http://dx.doi.org/10.1242/dmm.012054
69. Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, Katibah GE, Amora R, Boydston EA, Zeitler B, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 2009; 27:851-7; PMID:19680244; http://dx.doi.org/10.1038/nbt.1562
70. Bobis-Wozowicz S, Osiak A, Rahman SH, Cathomen T. Targeted genome editing in pluripotent stem cells using zinc-finger nucleases. Methods 2011; 53:339-46; PMID:21185378; http://dx.doi.org/10.1016/j.ymeth.2010.12.019
71. Park KE, Telugu BP. Role of stem cells in large animal genetic engineering in the TALENs-CRISPR era. Reprod Fertil Dev 2013; 26:65-73; PMID:24305178; http://dx.doi.org/10.1071/RD13258
72. Fabarius A, Li R, Yerganian G, Hehlmann R, Duesberg P. Specific clones of spontaneously evolving karyotypes generate individuality of cancers. Cancer Genet Cytogenet 2008; 180:89-99; PMID:18206533; http://dx.doi.org/10.1016/j. cancergencyto.2007.10.006
73. Duesberg P, Li R, Fabarius A, Hehlmann R. The chromosomal basis of cancer. Cell Oncol 2005; 27:293-318; PMID:16373963
74. Nicholson JM, Duesberg P. On the karyotypic origin and evolution of cancer cells. Cancer Genet Cytogenet 2009; 194:96-110; PMID:19781442; http://dx.doi.org/10.1016/j.cancergencyto.2009.06.008
75. Tang YC, Williams BR, Siegel JJ, Amon A. Identification of aneuploidy-selective antiproliferation compounds. Cell 2011; 144:499-512; PMID:21315436; http://dx.doi.org/10.1016/j.cell.2011.01.017
76. Manchado E, Malumbres M. Targeting aneuploidy for cancer therapy. Cell 2011; 144:465-6; PMID:21335229; http://dx.doi.org/10.1016/j.cell.2011.01.037
77. Holland AJ, Cleveland DW. Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep 2012; 13:501-14; PMID:22565320; http://dx.doi.org/10.1038/embor.2012.55
78. Pfau SJ, Amon A. Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep 2012; 13:515-27; PMID:22614003; http://dx.doi.org/10. 1038/embor.2012.65
79. Jiang J, Jing Y, Cost GJ, Chiang JC, Kolpa HJ, Cotton AM, Carone DM, Carone BR, Shivak DA, Guschin DY, et al. Translating dosage compensation to trisomy 21. Nature 2013; 500:296-300; PMID:23863942; http://dx.doi.org/10.1038/ nature12394
80. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, Nagano H, Sekimoto M, Doki Y, Mori M. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA 2010; 107:40-5; PMID:20018687; http://dx.doi.org/10.1073/pnas.0912407107
81. Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene 2013; 32(2260.e1-21):2249-60, e1-21; PMID:22777357; http://dx.doi.org/10.1038/onc.2012.237
82. Lang JY, Shi Y, Chin YE. Reprogramming cancer cells: back to the future. Oncogene 2013; 32:2247-8; PMID:22869153; http://dx.doi.org/10.1038/onc.2012.349
83. Kim J, Hoffman JP, Alpaugh RK, Rhim AD, Reichert M, Stanger BZ, Furth EE, Sepulveda AR, Yuan CX, Won KJ, et al. An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep 2013; 3:2088-99; PMID:23791528; http://dx.doi.org/10.1016/ j.celrep.2013.05.036
84. Ramos-Mejia V, Fraga MF, Menendez P. iPSCs from cancer cells: challenges and opportunities. Trends Mol Med 2012; 18:245-7; PMID:22521522; http://dx.doi.org/10.1016/j.molmed.2012.04.001
85. Abad M, Mosteiro L, Pantoja C, Cañamero M, Rayon T, Ors I, Graña O, Megías D, Domínguez O, Martínez D, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature 2013; 502:340-5; PMID:24025773; http://dx.doi.org/10.1038/ nature12586
86. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010; 143:508-25; PMID:21074044; http://dx.doi.org/10.1016/j.cell.2010.10.008
87. Martinez Arias A, Brickman JM. Gene expression heterogeneities in embryonic stem cell populations: origin and function. Curr Opin Cell Biol 2011; 23:650-6; PMID:21982544; http://dx.doi.org/10.1016/j.ceb.2011.09.007
88. Huang S. Reprogramming cell fates: reconciling rarity with robustness. Bioessays 2009; 31:546-60; PMID:19319911; http://dx.doi.org/10.1002/bies. 200800189
89. Maenhaut C, Dumont JE, Roger PP, van Staveren WC. Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis 2010; 31:149-58; PMID:19858069; http://dx.doi.org/10.1093/carcin/bgp259
90. Floor SL, Dumont JE, Maenhaut C, Raspe E. Hallmarks of cancer: of all cancer cells, all the time? Trends Mol Med 2012; 18:509-15; PMID:22795735; http://dx.doi.org/10.1016/j.molmed.2012.06.005
91. Li Y, Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer Res 2012; 72:576-80; PMID:22298594; http://dx.doi.org/10.1158/0008-5472.CAN-11-3070
92. Antoniou A, Hébrant A, Dom G, Dumont JE, Maenhaut C. Cancer stem cells, a fuzzy evolving concept: A cell population or a cell property? [Epub ahead of print]. Cell Cycle 2013; 12:3743-8; PMID:24270846; http://dx.doi.org/ 10.4161/cc.27305